Nature pulls GSK paper

Share this article:

Nature has officially dumped a 2010 research article about a then-experimental MS medication via retraction, reports BioCentury. The retracted paper came under scrutiny earlier this year, after GlaxoSmithKline fired its research head in China, Jiangwu Zang, upon “discovering that a study...contained misrepresentation of data,” according to Reuters which covered the firing in June.

The employee dismissal was soon followed by coverage in which Liu Xuebin, one of the other dismissed researchers, told Bloomberg in August that GSK created a high-stress, competitive environment in which mistakes can happen and corners cut. He also said that the MS study, which labeled healthy MS cells as from healthy subjects, should not be thrown out.

GSK said in a statement Dec. 5 that it investigated the matter and recommended Nature retract the paper. The company said in the statement that it “still believes the investigational drug and the signaling pathway may have potential in other disease states,” but that it is no longer exploring the MS application. GSK said a total of five R&D employees associated with the paper (which had 18 authors) are no longer with the company.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.